TABLE 4.

Unadjusted 2- and 10-week mortality outcomes for the five combination treatment regimens in the Advancing Cryptococcal Treatment in Africa trial.

Regimen	2-week mortality			10-week mortality
	n/N	%	95% CI	n/N	%	95% CI
One-week amphotericin B and flucytosine (short course)	13/113	11.6	5.7–17.5	27/113	24.2	16.2–32.1
Two-week fluconazole and flucytosine (all-oral regimen)	41/225	18.2	13.2–23.3	79/225	35.1	28.9–41.3
Two-week amphotericin B and flucytosine	24/115	20.9	13.4–28.3	44/115	38.3	29.4–47.2
Two-week amphotericin B and fluconazole	25/114	21.9	14.3–29.5	47/114	41.3	32.3–50.4
One-week amphotericin B and fluconazole	36/111	32.4	23.7–41.1	54/111	48.6	39.4–57.9

CI, confidence interval; n/N, number of deaths divided by number of participants in that trial arm.